FDA approves Moderna’s updated COVID-19 vaccines for 2026-2027

The U.S. Food and Drug Administration (FDA) has approved Moderna's updated COVID-19 vaccines, Spikevax and mNEXSPIKE, for the 2026-2027 season, according to a press release from the company. These updated vaccines contain the JN.1-lineage XFG subvariant of SARS-CoV-2, as recommended by the FDA. The 2026-2027 formula for Spikevax has received approval in several countries, including Europe, South Korea, Singapore, Switzerland, and the United Kingdom.

The 2026-2027 formula for mNEXSPIKE has been approved by regulators in Japan. Additional regulatory applications are under review globally. Moderna CEO Stéphane Bancel emphasized that COVID-19 remains a serious public health threat, responsible for numerous outpatient visits and hospitalizations in the U.S. last year alone. The updated vaccines are expected to be available in the coming days.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.